

Thinking Out Loud

Biofabrication of Autologous Human Hepatocytes for Transplantation: How Do We Get There?

Nandini Agarwal,*† Branimir Popovic,† Nicole J. Martucci,†
Nicolas A. Fraunhoffer,†‡§ and Alejandro Soto-Gutierrez†

*School of Bioscience and Technology, Vellore Institute of Technology, Vellore, India

†Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

‡Facultad de Ciencias de la Salud, Carrera de Medicina, Universidad Maimónides,

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

§Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina

Directed differentiation of hepatocytes from induced pluripotent stem cells (iPSCs) holds promise as source material for treating some liver disorders. The unlimited availability of perfectly differentiated iPSC-derived hepatocytes will dramatically facilitate cell therapies. While systems to manufacture large quantities of iPSC-derived cells have been developed, we have been unable to generate and maintain stable and mature adult liver cells *ex vivo*. This short review highlights important challenges and possible solutions to the current state of hepatocyte biofabrication for cellular therapies to treat liver diseases. Successful cell transplantation will require optimizing the best cell function, overcoming limitations to cell numbers and safety, as well as a number of other challenges. Collaboration among scientists, clinicians, and industry is critical for generating new autologous stem cell-based therapies to treat liver diseases.

Key words: Hepatocyte proliferation; Liver regeneration

INTRODUCTION

The demand for transplantable livers has increased progressively, outpacing the supply of live and cadaveric organs; this results in longer waiting time for the patients, reducing their prospective survival rate¹. Additionally, it is projected that the demand for livers will increase by 10% in 10 years and 23% in 20 years¹. Several strategies have been explored to increase the number of livers available for transplantation: i) The use of marginal donors (e.g., donors over the age of 60; donors with greater than 30% hyponatremia or macrosteatosis, donors with positive serologies for the hepatitis C or hepatitis B virus, donors with a cold ischemia time of greater than 12 h, non-heart-beating donors, and grafts from split livers or living related donors)²; ii) machine perfusion approaches to resuscitate marginal donor livers³; and iii) novel cell therapies to induce tolerance⁴. However, if successful, these approaches are estimated to have limited impact

on the organ donor pool¹. New regenerative approaches to investigating the liver organogenesis seek to provide novel insights into liver repopulation. Liver cell therapy has been under intensive investigation for decades⁵ and seen as a promising potential alternative to orthotopic liver transplantation. We have learned that the ideal candidates for this kind of therapy are individuals with acute liver failure and liver-based inborn errors of metabolism^{6,7}. Indeed, published experiences of liver cell therapy in the treatment of these conditions have shown promising results⁵. However, only partial correction of metabolic disorders has been achieved, and liver cell therapy has not shown to reliably circumvent the need for traditional organ transplant. While a detailed clinical report is beyond the scope of this article, it is noted that significant barriers persist limiting broader implementation of liver cell therapy that has been highlighted in a recent report that included a preclinical and clinical

Address correspondence to Alejandro Soto-Gutierrez, M.D., Ph.D., Department of Pathology, University of Pittsburgh, 200 Lothrop Street, 423 Biomedical Science Tower, Pittsburgh, PA 15213, USA. Tel: (412) 648-0064; Fax: (412) 648-1916; E-mail: als208@pitt.edu or Nicolas A. Fraunhoffer, Ph.D., Facultad de Ciencias de la Salud, Carrera de Medicina, Universidad Maimónides, Hidalgo 775, Buenos Aires C1405BCK, Argentina. Tel: (0011) 4905-1110; E-mail: nicolasfraunhoffernavarro@gmail.com

approach⁸. The most important hurdles identified, besides the well recognized lack of hepatocyte source for transplantation, were i) the ability to monitor the function and rejection of transplanted cells and ii) the ability to control rejection episodes in vivo. Thus, given the short-term graft survival and immunological hurdles that have been identified in the latest hepatocyte allotransplantation trials, autologous gene-corrected and fully functional hepatocytes would be a desirable solution.

The aim of this minireview is to critically evaluate the current state of biofabricating autologous human hepatocytes, underscoring important advancements that have occurred in the expanding field of cell engineering and discuss new exciting technologies that have the potential to change the landscape of liver replacement once and for all.

CHALLENGES IN GENERATING AUTOLOGOUS HUMAN HEPATOCYTES FOR TRANSPLANTATION

Induced Pluripotent Stem Cell-Derived Hepatocytes

Induced pluripotent stem cells (iPSCs) can be expanded indefinitely and differentiate into all cell types of the body, while maintaining genetic stability and are therefore a promising cell source of functional autologous hepatocytes⁹. Human iPSCs are generated by forced expression of specific pluripotency transcription factors¹⁰. Great progress has been made in exploring the differentiation capacity of iPSCs toward the hepatocyte lineage. Generating hepatocyte-like cells (HLCs) from iPSC is necessary taking into account multiple factors related to the differentiation process: extracellular matrix, media, and small molecules and supplements to provide adequate and in a timely manner cell signaling to guide pluripotent stem cells toward a definitive endoderm and finally hepatocyte-like cells. Great progress has been made in exploring the differentiation capacity of PSCs toward the hepatocyte lineage. Although specific culture conditions can differ, most protocols share a general three-step strategy based on liver development studies. The three basic steps are endoderm induction, generation of hepatic progenitors or hepatoblasts, and hepatocyte maturation. The endoderm induction is characterized by the use of activin A, FGF, and BMP4, which, together with the activation of WNT3, signal trigger the generation of endoderm cells^{11–15}. The WNT pathway activation promotes FOXA2 activation via SOX17¹⁶. The differentiation to hepatic progenitor or hepatoblasts is generated by the addition of HGF that induce the expression of HNF4^{17–19} and fetoprotein²⁰. Other hepatic inducers include FGF2, FGF4, and BMP4. Finally, hepatocyte maturation is the most critical step during generation of HLCs. Commonly oncostatin M (an interleukin-6-related protein) and dexamethasone (a glucocorticoid) are used to induce the expression of hepatocyte markers, such

as albumin, CK18, some cytochrome p450, SERPINA1, ASGPR1, C/EBP β , and UGT1A1²¹. Additionally, some functional assays, such as urea production, LDL uptake, and albumin production are used to evaluate the HLCs to primary hepatocytes²². Unfortunately, stem cell-derived HLCs do not possess all functions of mature hepatocytes. Liver maturation is complex and dynamic; full maturation in humans can take as long as 2 years from birth and involves expression of several signaling pathways, such as those responsible for bile acid synthesis, drug metabolism, and amino acid transport. Current efforts in many laboratories are focused on the study of components that promote hepatocyte differentiation and maturation including growth factors, transcription factors, microRNAs, small molecules, and the microenvironment. Despite progress in advancing the differentiation of human stem cells into hepatocytes in vitro, cells that replicate the ability of human primary adult hepatocytes to proliferate and completely replace livers for clinical applications have not been achieved^{9,23}. Moreover, HLCs usually show a fetal phenotype and function^{24,25}.

To generate a functional hepatocyte, it is necessary to take into consideration the developmental pathways and the developmental microenvironment where interactions with other cells and their extracellular matrix may provide specific maturation cues^{25–27}. However, despite the successful use of growth factors and cytokines to design protocols for definitive endoderm and approaches to promote hepatocyte specification, the implementation of approaches for final hepatocyte maturation remains elusive^{25–27}. Components that promote hepatocyte maturation including the dynamic changes that occurred after birth in the human liver (microbiota, circulation, nutrition) that could be potentially used for in vitro approaches have been discussed elsewhere²².

Gene-Edited Hepatocytes: Essential for Autologous Transplantation

CRISPR/Cas9 system was reported for the first time in 1987²⁸, but it was not until 2005 that it was postulated as an immune adaptive system to multiple species of bacteria²⁹. The natural function of this system is recognizing foreign DNA sequences in the bacterial genome and promoting host protection through the destruction of these sequences. However, the major milestone in the development of CRISPR/Cas9 was its application in mammalian cells to potentially treat multiple genetic diseases.

One could imagine two future scenarios. The first and more logical scenario is to genetically correct the defect directly in the patient via viral delivery systems [e.g., adeno-associated virus (AAV)]; however, this approach has been more challenging³⁰. The targeting efficiency in somatic cells has been relatively modest (<1%) and failed to yield a distinct phenotype³¹. Alternatively, in

vivo selection was required to enrich the gene-edited cells³², limiting its application to only those genes that conferred a selective growth and survival advantage in vivo [e.g., fumarylacetoacetate hydrolase (Fah)]. Other disadvantages that have been detected using AAV are related to its known inflammatory properties following systemic administration that often provoke liver toxicity and rapid immune clearance of gene-modified cells³³ and the likelihood of undesired genome editing in nontarget tissues or nonspecific off-target editing^{34,35}. These limitations justify the development and validation of robust tissue-specific in vivo gene-editing platforms (e.g., lipid nanoparticles^{36,37}, mRNA³⁸) that further minimize the risk of off-target gene editing in nontarget genes and/or nontarget tissues in the near future. The second scenario that one could imagine is where liver tissue could be collected from patients with monogenic diseases, and gene correction could be achieved in vitro using the CRISPR/CAS9 system. Those cells, which successfully underwent functional gene correction, could then be selected and amplified in vivo using xenograft animal models to grow hepatocytes. A critical mass of modified, mature hepatocytes would be produced, which would enable the original patient/donor to receive an autologous hepatocyte transplantation of their own genetically corrected cells. Hurdles to this approach would need to be overcome, including exposing patients to risky surgical resections and quickening the process of gene correction and selection, as isolated human hepatocytes are known to undergo rapid dedifferentiation in vitro. However, other cell sources could be used (e.g., human iPSC-derived hepatocytes).

The number of studies that use human primary hepatocytes for gene editing is limited. This is related to the lack of efficient repopulation of animal models to evaluate these cells in vivo. Wang et al. reported for the first time the knockdown of the *PCSK9* gene in human hepatocytes in vivo using the AVV- CRISPR/Cas9 system in FRG mouse model with a 47% efficiency³⁹. Despite these promising results, the use of AVV has been related to hepatic injury due to AVV-induced immunogenicity⁴⁰. The implementation of an alternative less immunogenic delivery system for CRISPR/Cas9, such as lipid nanoparticles, might resolve the immunological damage.

CRISPR/Cas9 gene editing can be used for the treatment of monogenic liver diseases, caused by loss-of-function mutations or deficient gene expression. The most recent approaches in hepatocyte gene editing have been used for treatment of metabolic diseases in in vivo systems. Yin et al. demonstrated the application in vivo of CRISPR/Cas9 system to correct the *Fah* mutation in a model of hereditary tyrosinemia type 1 (HT1), using hydrodynamic injection of Cas9-encoded plasmid and ssDNA donor template. This approach resulted in 33%

corrected hepatocytes³². In a similar study, Yang et al. corrected ornithine transcarbamylase (OTC) deficiency, through the administration of AAV containing a CRISPR/Cas9 system in neonatal OTC mice; they showed a reversion of the mutation in 10% of hepatocytes⁴¹. Interestingly, the same protocol applied to adult OTC mice resulted in 1.7% corrected hepatocytes, which was insufficient to rescue the OTC phenotype²⁰. These results suggest a different pattern of response to gene editing in relation to hepatocyte maturation state.

If human iPSC-derived hepatocytes were to be used, then we envision the requirement of collection of any cells (e.g., blood, skin fibroblast, epithelial cells, etc.) from patients with monogenic diseases, as there are well-established protocols for in vitro culture and expansion of these types of cells. After that, these cells could be reprogrammed to pluripotency to generate iPSCs, and gene correction could be achieved in vitro using the CRISPR/Cas9 system. Moreover, screening and selection for the best clones after gene editing would not be a burden. Resulting iPSCs can be screened and then undergo hepatocyte-directed differentiation. These HLCs could be amplified in vivo using xenograft animal models to grow hepatocytes. A critical mass of modified, mature hepatocytes would be produced, which would enable autologous hepatocyte transplantation (Fig. 1).

In Vivo Bioreactors to Expand Autologous Hepatocytes

To improve the amount and the maturation stage of the HLCs generated from iPSCs, animals could be used as in vivo bioreactors to mature and biofabricate large amounts of functional human hepatocytes for transplantation. As discussed below, liver tissue could be collected from patients with monogenic diseases, hepatocytes could be isolated, and gene correction could be achieved in vitro using the CRISPR/CAS9 system. Those cells that successfully underwent functional gene correction could then be selected and amplified in vivo using xenograft animal models to grow hepatocytes. A sufficient cellular mass of modified, mature hepatocytes would be produced, which would enable the original patient/donor to receive an autologous hepatocyte transplantation of their own genetically corrected cells. In fact, human hepatocyte gene correction has been reported^{39,42} (Fig. 1).

Genetically modified animals are the most suitable models to be used as a bioreactor. These models provide transplanted hepatocytes a strong advantage related to growth and repopulation of the host liver. Overexpression of an albumin–urokinase type plasminogen activator (uPA) fusion construct, which increases uPA concentration promoting liver damage, enables the transplanted cells to reconstitute over 90% of the liver mass⁴³. In recent years, the most used animal model to evaluate the liver repopulation is the FRG; this mouse carries three knockout




Figure 1. Schematic representation of manufacturing approach of autologous hepatocytes for transplantation. Primary hepatocytes are isolated from the patient and edited with CRISPR/Cas9 to correct the pathogenic genomic alteration ex vivo. Then the edited primary hepatocytes are selected and multiplied in a “bioreactor” to be transplanted in patients. Alternatively, fibroblasts/blood cells are isolated from the patient and edited for pathogenic mutations using CRISPR/Cas9 ex vivo. The cells are then screened and reprogrammed to produce induced pluripotent stem cells (iPSCs) in vitro. These corrected iPSCs are differentiated to generate hepatocytes, which are transplanted into a “bioreactor” to produce functional hepatocytes that can be used for transplantation in patients.

genes: fumarylacetoacetate hydrolase knockout (*Fah*^{-/-}), recombinase 2 gene (*Rag2*) knockout, and IL2 receptor chain gene (*Il2rg*) knockout. *Fah*^{-/-} modification offers the possibility to control liver injury using (2-nitro-4-trifluoro-methyl-benzoyl)-1, 3 cyclohexanedione (NTBC), which avoids the accumulation of degradation products of phenylalanine and tyrosine, whereas *Rag2* and *Il2rg* knockout reduce the action of the immunological system on the transplanted hepatocytes⁴⁴.

In relation to the previous mentioned approaches, Zhu et al. reported for the first time a method to overcome the pluripotent state to generate HLCs⁴⁵. The process involved reprogramming the fibroblasts with OCT4, SOX2, and KLF4 to induce a plastic state, and then after 3 days the hepatocyte differentiation protocol was continued. The cells showed the common HLC features such as albumin production, HNF4 expression, and cytochrome activity. The authors argued that this approach reduced the tumor risk related to the expression of the pluripotency-specific

genes. However, after transplantation (9 months) into FRG mice, the cells only achieved a 2% liver repopulation. Importantly, this study showed that the HLCs generated in vitro could mature after transplantation, showing a gene expression profile similar to adult hepatocytes after laser capturing of liver repopulated nodules.

In order to generate large amounts of human hepatocytes in live bioreactors, mice naturally would not be suitable for this purpose due to the size restrictions. The pig is a more appropriate model because of its similarity in size, anatomy, and biology to humans⁴⁶. It has been reported that generated and characterized *FAH*^{-/-} pigs⁴⁷ could be used to generate human hepatocytes. Moreover, severe combined immunodeficiency (SCID) pigs have been generated (naturally tolerant of xenotransplantation)⁴⁸ that could potentially be used to produce human hepatocytes in combination with systems to exacerbate their liver repopulation abilities. Hurdles to this approach would need to be overcome, including establishment of

facilities and protocols necessary to obtain clean piglets and the high cost associated to it⁴⁹. One more potential less costly and more practical option is the use of rats as bioreactors. Assuming that SCID rats preconditioned to repopulate its liver with human hepatocytes can be created, one can easily obtain $5\text{--}6 \times 10^8$ viable cells per rat liver. A total of 2.0×10^8 viable cells/kg is a hepatocyte dose that is proven to be safe and, to a certain degree, effective in humans⁸. Most candidates for cell therapy are small children with genetic liver disorders⁸; thus, only two to four rat livers would be necessary to treat a pediatric patient (weighting up to 12 kg).

Culturing and gene correction of human iPSCs is an unexplored path with little research performed. Some evidence of the application of human iPSCs to correct metabolic and genetic disorders has been seen in *in vitro* conditions^{50–52}. Zhang et al. have described a differentiation protocol to produce gene-corrected human iPSCs to treat Wilson's disease, which is caused by a mutation in the ATP7B gene resulting in a defective protein transporter in the liver⁵¹. Gene correction reversed the effects of this genetic disease *in vitro*. In a similar fashion, Yusa et al. used a combination of zinc finger nucleases (ZNFs) and *piggyBac* technology in human iPSCs to achieve biallelic correction of a point mutation (Glu342Lys) to correct α_1 -antitrypsin deficiency. They reported this method as being more efficient than CRISPR-mediated systems by preventing contamination of the host genome with residual nonhuman sequences⁵⁰.

The major challenge in using gene editing is off-target point mutations where the base pairing between the target site and the sgRNA of Cas9 may not be perfect, leading to cleavage at sites with multiple mismatches⁵³. A major concern of this mosaicism is the potential of tumor development *in vivo*. Point mutations can also occur while culturing human iPSCs *in vitro*. Yoshihara et al. have reported the presence of *de novo* mutations that can occur due to genetic reprogramming of somatic cells to produce iPSCs⁵⁴. These mutations are underrepresented but can cause severe DNA damage and have tumorigenic potential. The type of somatic cells and the method used to make iPSCs can also affect the occurrence of point mutations⁸. Araki et al. generated nuclear transfer embryonic stem cells (ntESCs) from mouse embryonic fibroblasts (MEFs) and tail-tip fibroblasts (TTFs) and found fewer point mutations in TTF-derived iPSCs⁵⁵. It continues to be a major hurdle that needs to be overcome to make autologous transplantation with gene-corrected cells a reality.

ACKNOWLEDGMENTS: *This work was supported by grants from NIH, DK099257 to A.S.-G. B.P. and A.S.-G. are inventors on a pending patent application that describes the use of human induced pluripotent stem cells to biofabricate hepatocytes (PCT/US2018/018032). A.S.-G. is a cofounder and has a*

financial interest in Von Baer Wolff, Inc., a company focused on the production of autologous human hepatocytes from stem cell technology and programming liver failure, and their interests are managed by the Conflict of Interest Office at the University of Pittsburgh in accordance with their policies.

REFERENCES

- Habka D, Mann D, Landes R, Soto-Gutierrez A. Future economics of liver transplantation: A 20-year cost modeling forecast and the prospect of bioengineering autologous liver grafts. *PLoS One* 2015;10:e0131764.
- Zarrinpar A, Busuttil RW. Liver transplantation: Past, present and future. *Nat Rev Gastroenterol Hepatol*. 2013; 10(7):434–40.
- Graham JA, Guarrera JV. “Resuscitation” of marginal liver allografts for transplantation with machine perfusion technology. *J Hepatol*. 2014;61(2):418–31.
- Geissler EK, Hutchinson JA. Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients. *Curr Opin Organ Transplant*. 2013;18(4):408–15.
- Puppi J, Strom SC, Hughes RD, Bansal S, Castell JV, Dagher I, Ellis EC, Nowak G, Ericzon BG, Fox IJ, Gómez-Lechón MJ, Guha C, Gupta S, Mitry RR, Ohashi K, Ott M, Reid LM, Roy-Chowdhury J, Sokal E, Weber A, Dhawan A. Improving the techniques for human hepatocyte transplantation: Report from a consensus meeting in London. *Cell Transplant*. 2012;21(1):1–10.
- Soltys KA, Soto-Gutierrez A, Nagaya M, Baskin KM, Deutscher M, Ito R, Shneider BL, Squires R, Vockley J, Guha C, Roy-Chowdhury J, Strom SC, Platt JL, Fox IJ. Barriers to the successful treatment of liver disease by hepatocyte transplantation. *J Hepatol*. 2010;53(4):769–74.
- Squires JE, Soltys KA, McKiernan P, Squires RH, Strom SC, Fox J, Soto-Gutierrez A. Clinical hepatocyte transplantation: What is next? *Curr Transpl Rep*. 2017;4:280–9.
- Soltys KA, Setoyama K, Tafaleng EN, Soto-Gutiérrez A, Fong J, Fukumitsu K, Nishikawa T, Nagaya M, Sada R, Haberman K, Gramignoli R, Dorko K, Tahan V, Dreyzin A, Baskin K, Crowley JJ, Quader MA, Deutsch M, Ashokkumar C, Shneider BL, Squires RH, Ranganathan S, Reyes-Mugica M, Dobrowolski SF, Mazariegos G, Elango R, Stolz DB, Strom SC, Vockley G, Roy-Chowdhury J, Cascalho M, Guha C, Sindhi R, Platt JL, Fox IJ. Host conditioning and rejection monitoring in hepatocyte transplantation in humans. *J Hepatol*. 2017;66(5):987–1000.
- Rezvani M, Grimm AA, Willenbring H. Assessing the therapeutic potential of lab-made hepatocytes. *Hepatology* 2016;64(1):287–94.
- Takahashi K, Tanabe M, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007;131(5):861–72.
- Touboul T, Hannan NR, Corbinau S, Martinez A, Martinez C, Branchereau S, Mainot S, Strick-Marchand H, Pedersen R, Di Santo J, Weber A, Vallier L. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. *Hepatology* 2010;51(5):1754–65.
- Yamanaka Y, Ralston A. Early embryonic cell fate decisions in the mouse. *Adv Exp Med Biol*. 2010;695(01/2010): 1–13.
- Vallier L1, Touboul T, Chng Z, Brimpari M, Hannan N, Millan E, Smithers LE, Trotter M, Rugg-Gunn P, Weber A,

- Pedersen RA. Early cell fate decisions of human embryonic stem cells and mouse epiblast stem cells are controlled by the same signaling pathways. *PLoS One* 2009;4(6):e6082.
14. Teo AK1, Ali Y, Wong KY, Chipperfield H, Sadasivam A, Poobalan Y, Tan EK, Wang ST, Abraham S, Tsuneyoshi N, Stanton LW, Dunn NR. Activin and BMP4 synergistically promote formation of definitive endoderm in human embryonic stem cells. *Stem Cells* 2012;30(4):631–42.
 15. Toivonen S1, Lundin K, Balboa D, Ustinov J, Tamminen K, Palgi J, Trokovic R, Tuuri T, Otonkoski T. Activin A and Wnt-dependent specification of human definitive endoderm cells. *Exp Cell Res*. 2013;319(17):2535–44.
 16. Engert S, Burtscher I, Liao WP, Dulev S, Schotta G, Lickert H. Wnt/ β -catenin signalling regulates Sox17 expression and is essential for organizer and endoderm formation in the mouse. *Development* 2013;140(15):3128–38.
 17. Kamiya A, Kinoshita T, Miyajima A. Oncostatin M and hepatocyte growth factor induce hepatic maturation via distinct signaling pathways. *FEBS Lett*. 2001;492(1–2):90–4.
 18. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschieche W, Sharpe M, Gherardi E, Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. *Nature* 1995;373(6516):699–702.
 19. Duncan SA, Manova K, Chen WS, Hoodless P, Weinstein DC, Bachvarova RF, Darnell JE Jr. Expression of transcription factor HNF-4 in the extraembryonic endoderm, gut, and nephrogenic tissue of the developing mouse embryo: HNF-4 is a marker for primary endoderm in the implanting blastocyst. *Proc Natl Acad Sci USA* 1994;91(16):7598–602.
 20. Gualdi R, Bossard P, Zheng M, Hamada Y, Coleman JR, Zaret KS. Hepatic specification of the gut endoderm in vitro: Cell signaling and transcriptional control. *Genes Dev*. 1996;10:1670–82.
 21. Hannoun Z, Steichen C, Dianat N, Webe A, Dubart-Kupperschmitt A. The potential of induced pluripotent stem cell derived hepatocytes. *J Hepatol*. 2016;65(1):182–99.
 22. Chen C, Soto-Gutierrez A, Baptista PM, Spee B. Biotechnology challenges to in vitro maturation of hepatic stem cells. *Gastroenterology* 2018;154(5):1258–72.
 23. Gerbal-Chaloin S, Funakoshi N, Caillaud A, Gondeau C, Champon B, Si-Tayeb K. Human induced pluripotent stem cells in hepatology: Beyond the proof of concept. *Am J Pathol*. 2014;184(2):332–47.
 24. Camp JG, Sekine K, Gerber T, Loeffler-Wirth H, Binder H, Gac M, Kanton S, Kageyama J, Damm G, Seehofer D, Belicova L, Bickle M, Barsacchi R, Okuda R, Yoshizawa E, Kimura M, Ayabe H, Taniguchi H, Takebe T, Treutlein B. Multilineage communication regulates human liver bud development from pluripotency. *Nature* 2017;546(7659):533–8.
 25. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR, Ueno Y, Zheng YW, Koike N, Aoyama S, Adachi Y, Taniguchi H. Vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature* 2013;499(7459):481–4.
 26. Soto-Gutierrez A, Kobayashi N, Rivas-Carrillo JD, Navarro-Alvarez N, Zhao D, Okitsu T, Noguchi H, Basma H, Tabata Y, Chen Y, Tanaka K, Narushima M, Miki A, Ueda T, Jun HS, Yoon JW, Lebkowski J, Tanaka N, Fox JJ. Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. *Nat Biotechnol*. 2006;24:1412–9.
 27. Soto-Gutierrez A, Navarro-Alvarez N, Zhao D, Rivas-Carrillo JD, Lebkowski J, Tanaka N, Fox JJ, Kobayashi N. Differentiation of mouse embryonic stem cells to hepatocyte-like cells by co-culture with human liver nonparenchymal cell lines. *Nat Protoc*. 2007;2:347–56.
 28. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in *Escherichia coli*, and identification of the gene product. *J Bacteriol*. 1987;169:5429–33.
 29. Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. *Microbiology* 2005;151:2551–61.
 30. Singh K, Evens H, Nair N, Rincón MY, Sarcar S, Samara-Kuko E, Chuah MK, VandenDriessche T. Efficient in vivo liver-directed gene editing using CRISPR/Cas9. *Mol Ther*. 2018;26(5):1241–54.
 31. Senís E, Fatouros C, Große S, Wiedtke E, Niopek D, Mueller AK, Börner K, Grimm D. CRISPR/Cas9-mediated genome engineering: An adeno-associated viral (AAV) vector toolbox. *Biotechnol J*. 2014;9(11):1402–12.
 32. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Kotliansky V, Sharp PA, Jacks T, Anderson DG. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. *Nat Biotechnol*. 2014;32(6):551–3.
 33. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. *Gene Ther*. 2003;10(11):955–63.
 34. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nat Biotechnol*. 2013;31(9):822–6.
 35. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F. DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat Biotechnol*. 2013;31(9):827–32.
 36. Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, Dirstine T, Ciullo C, Lescarbeau R, Seitzer J, Shah RR, Shah A1, Ling D, Growe J, Pink M1, Rohde E, Wood KM, Salomon WE, Harrington WF, Dombrowski C, Strapps WR, Chang Y, Morrissey DV. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. *Cell Rep*. 2018;22(9):2227–35.
 37. Wang M, Zuris JA, Meng F, Rees H, Sun S, Deng P, Han Y, Gao X, Pouli D, Wu Q, Georgakoudi I, Liu DR, Xu Q. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. *Proc Natl Acad Sci USA* 2016;113(11):2868–73.
 38. Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ, Lynn A, Bulychev A, McFadyen I, Chan J, Almarsson Ö, Stanton MG, Benenato KE. A Novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates. *Mol Ther*. 2018;26(6):1509–19.
 39. Wang X, Raghavan A, Chen T, Qiao L, Zhang Y, Ding Q, Musunuru K. CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo—Brief report. *Arterioscler Thromb Vasc Biol*. 2016;36(5):783–6.
 40. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple

- chemokines and acute neutrophil-dependent hepatic injury in vivo. *Hum Gene Ther.* 1999;10(6):965–76.
41. Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, Yu H, Xu C, Morizono H, Musunuru K, Batshaw ML, Wilson JM. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. *Nat Biotechnol.* 2016;34(3):334–8.
 42. Borel F, Tang Q, Gernoux G, Greer C, Wang Z, Barzel A, Kay MA, Shultz LD, Greiner DL, Flotte TR, Brehm MA, Mueller C. Survival advantage of both human hepatocyte xenografts and genome-edited hepatocytes for treatment of α -1 antitrypsin deficiency. *Mol Ther.* 2017;25(11):2477–89.
 43. Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. *Cell* 1991;66(2):245–56.
 44. Alwahsh SM, Rashidi H, Hay DC. Liver cell therapy: Is this the end of the beginning? *Cell Mol Life Sci.* 2018;75(8):1307–24.
 45. Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, Willenbring H, Ding S. Mouse liver repopulation with hepatocytes generated from human fibroblasts. *Nature* 2014;508:93–7.
 46. Cooper DK, Gollackner B, Sachs DH. Will the pig solve the transplantation backlog? *Annu Rev Med.* 2002;53(1):133–47.
 47. Hickey RD, Mao SA, Glorioso J, Lillegard JB, Fisher JE, Amiot B, Rinaldo P, Harding CO, Marler R, Finegold MJ, Grompe M, Nyberg SL. Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease. *Stem Cell Res.* 2014;13(1):144–53.
 48. Waide EH, Dekkers JC, Ross JW, Rowland RR, Wyatt CR, Ewen CL, Evans AB, Thekkoot DM, Boddicker NJ, Serão NV, Ellinwood NM, Tuggle CK. Not all SCID pigs are created equally: Two independent mutations in the Artemis gene cause SCID in pigs. *J Immunol.* 2015;195(7):3171–79.
 49. Powell EJ, Charley S, Boettcher AN, Varley L, Brown J, Schroyen M, Adur MK, Dekkers S, Isaacson D, Sauer M, Cunnick J, Ellinwood NM, Ross JW, Dekkers JC, Tuggle CK. Creating effective biocontainment facilities and maintenance protocols for raising specific pathogen-free, severe combined immunodeficient (SCID) pigs. *Lab Anim.* 2018;52(4):402–12.
 50. Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu PQ, Paschon DE, Miranda E, Ordóñez A, Hannan NR, Rouhani FJ, Darche S, Alexander G, Marciniak SJ, Fusaki N, Hasegawa M, Holmes MC, Di Santo JP, Lomas DA, Bradley A, Vallier L. Targeted gene correction of α -1 antitrypsin deficiency in induced pluripotent stem cells. *Nature* 2011;478(7369):391–4.
 51. Zhang S, Chen S, Li W, Guo X, Zhao P, Xu J, Chen Y, Pan Q, Liu X, Zychlinski D, Lu H, Tortorella MD, Schambach A, Wang Y, Pei D, Esteban MA. Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. *Hum Mol Genet.* 2011;20(16):3176–87.
 52. Omer L, Hudson EA, Zheng S, Hoying JB, Shan Y, Boyd NL. CRISPR correction of a homozygous low-density lipoprotein receptor mutation in familial hypercholesterolemia induced pluripotent stem cells. *Hepatology* 2017;1(9):886–98.
 53. Pankowicz FP, Jarrett KE, Lagor WR, Bissig KD. CRISPR/Cas9: At the cutting edge of hepatology. *Gut* 2017;0:1–12.
 54. Yoshihara M, Araki R, Kasama Y, Sunayama M, Abe M, Nishida K, Kawaji H, Hayashizaki Y, Murakawa Y. Hotspots of de novo point mutations in induced pluripotent stem cells. *Cell Rep.* 2017;21(2):308–15.
 55. Araki R, Mizutani E, Hoki Y, Sunayama M, Wakayama S, Nagatomo H, Kasama Y, Nakamura M, Wakayama T, Abe M. The number of point mutations in induced pluripotent stem cells and nuclear transfer embryonic stem cells depends on the method and somatic cell type used for their generation. *Stem Cells* 2017;35:1189–96.